| 摘要 | 第3-8页 |
| ABSTRACT | 第8-9页 |
| Chapter 1 Literature Review | 第13-39页 |
| 1.1 Nanotheranostics | 第13-22页 |
| 1.1.1 Introduction of nanotheranostics | 第14-15页 |
| 1.1.2 Nanotheranostics in therapy | 第15-18页 |
| 1.1.3 Nanotheranostics in imaging | 第18-22页 |
| 1.2 Stimulate Responsive Nanocarriers | 第22-29页 |
| 1.2.1 Exogenous and endogenous stimulus responsive nanocarriers | 第22-27页 |
| 1.2.2 Organic pH responsive nanocarriers | 第27-28页 |
| 1.2.3 Inorganic pH responsive nanocarriers | 第28-29页 |
| 1.3 MRI Guided Nanocarrier System | 第29-31页 |
| 1.3.1 T_1 contrast agents | 第29-30页 |
| 1.3.2 T_2 contrast agents | 第30页 |
| 1.3.3 Progress of MRI contrast agents | 第30-31页 |
| 1.4 Drug and Imaging Agent Loading Methods of Nanotheranostics | 第31-36页 |
| 1.4.1 Covalent drug and imaging agent delivery systems | 第32-33页 |
| 1.4.2 Non-covalent drug and imaging agent delivery systems | 第33-34页 |
| 1.4.3 Hybrid drug and imaging agent delivery systems | 第34页 |
| 1.4.4 Imaging agent as drug carrier | 第34-36页 |
| 1.5 Novelty and Significance of This Project | 第36-39页 |
| Chapter 2 Synthesis of Camptothecin Phosphonates | 第39-51页 |
| 2.1 Introduction of camptothecin | 第39-40页 |
| 2.2 Materials and Instruments | 第40-42页 |
| 2.2.1 Materials | 第40-41页 |
| 2.2.2 Instruments | 第41-42页 |
| 2.3 Synthesis and Characterization of Camptothecin Phosphonate | 第42-47页 |
| 2.3.1 Synthesis of camptothecin phosphonate(CPT-P) | 第42-43页 |
| 2.3.2 Characterization of camptothecin phosphonate | 第43-45页 |
| 2.3.3 Results and discussion | 第45-47页 |
| 2.4 Synthesis and Characterization of Camptothecin Diphosphonate | 第47-51页 |
| 2.4.1 Synthesis of camptothecin diphosphonate(CPT-2P) | 第47-48页 |
| 2.4.2 Characterization of camptothecin diphosphonate | 第48页 |
| 2.4.3 Results and discussion | 第48-51页 |
| Chapter 3 Preparation and Characterization of Hybrid Nanocarriers | 第51-81页 |
| 3.1 Materials and Instruments | 第52-54页 |
| 3.1.1 Materials | 第52-53页 |
| 3.1.2 Instruments | 第53-54页 |
| 3.2 Preparation of Hybrid Nanocarriers | 第54-55页 |
| 3.3 The Optimization of Hybrid Nanocarriers | 第55-64页 |
| 3.3.1 The measurement of drug loading content | 第55-59页 |
| 3.3.2 The hydrodynamic diameters of different hybrid nanocarriers | 第59-61页 |
| 3.3.3 The serum stability of different types of hybrid nanocarriers | 第61-63页 |
| 3.3.4 Results and discussion | 第63-64页 |
| 3.4 Characterization of Hybrid Nanocarrier | 第64-68页 |
| 3.4.1 The storage stability of hybrid nanocarrier | 第64-65页 |
| 3.4.2 The morphology of hybrid nanocarriers | 第65-66页 |
| 3.4.3 Determination of Mn~(2+) content in hybrid nanocarriers | 第66-68页 |
| 3.4.4 Results and discussion | 第68页 |
| 3.5 In Vitro CPT-2P and Mn~(2+) Release | 第68-74页 |
| 3.5.1 In vitro CPT-2P release | 第68-70页 |
| 3.5.2 In vitro Mn~(2+) release | 第70-72页 |
| 3.5.3 Results and discussion | 第72-74页 |
| 3.6 In Vitro MRI Analysis | 第74-76页 |
| 3.6.1 In vitro MR relaxivity measurements | 第74-75页 |
| 3.6.2 Results and discussion | 第75-76页 |
| 3.7 Determination of ICG Loading in Hybrid Nanocarriers | 第76-81页 |
| 3.7.1 The preparation of LMnP/ICG-CPT-2P hybrid nanocarriers | 第76页 |
| 3.7.2 The fluorescent sensor(ICG)loading content | 第76-81页 |
| Chapter 4 In Vitro Study of Hybrid Nanocarriers | 第81-91页 |
| 4.1 Materials and Instruments | 第81-82页 |
| 4.1.1 Materials | 第81-82页 |
| 4.1.2 Instruments | 第82页 |
| 4.2 In Vitro Cytotoxicity | 第82-86页 |
| 4.2.1 The preparation of sample solution | 第83-84页 |
| 4.2.2 Results and discussion | 第84-86页 |
| 4.3 Cellular Uptake | 第86-88页 |
| 4.3.1 The procedure of cellular uptake test | 第86-87页 |
| 4.3.2 Results and discussion | 第87-88页 |
| 4.4 Hemocompatibility Analysis | 第88-91页 |
| 4.4.1 The procedure of hemocompatibility analysis | 第88-89页 |
| 4.4.2 Results and discussion | 第89-91页 |
| Chapter 5 In Vivo Study of Hybrid Nanocarriers | 第91-103页 |
| 5.1 Materials and Instruments | 第91-92页 |
| 5.1.1 Materials | 第91-92页 |
| 5.1.2 Instruments | 第92页 |
| 5.2 In Vivo MRI Measurements | 第92-95页 |
| 5.2.1 Establishment of mouse breast cancer model | 第92-93页 |
| 5.2.2 The procedure of in vivo MRI analysis | 第93页 |
| 5.2.3 Results and discussion | 第93-95页 |
| 5.3 Biodistribution and Pharmacokinetics | 第95-97页 |
| 5.3.1 The experiment of biodistribution and pharmacokinetics | 第95-96页 |
| 5.3.2 Results and discussion | 第96-97页 |
| 5.4 In Vivo Antitumor Efficacy | 第97-103页 |
| 5.4.1 In vivo antitumor efficacy study | 第97-99页 |
| 5.4.2 Histopathological and apoptosis analysis | 第99-101页 |
| 5.4.3 Results and discussion | 第101-103页 |
| Chapter6 Conclusion and Prospect | 第103-107页 |
| 6.1 Conclusion | 第103-105页 |
| 6.2 Prospect | 第105-107页 |
| Reference | 第107-117页 |
| Notes on publications and participation in scientific research | 第117-119页 |
| Acknowledgements | 第119-120页 |
